Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  European Journal of Cancer

• Publication date

  1996-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0959-8049(95)00641-9PMID 8814705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines

  2004cited by this paper
• Paclitaxel in cancer treatment

  1995cited by this paper
• Randomized Trial of Two Doses of Taxol in Metastatic Breast Cancer: An Interim Analysis

  1994cited by this paper
• Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

  1990cited by this paper
• Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

  1989cited by this paper
• Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.

  1988cited by this paper
• Taxol: an antimitotic agent with a new mechanism of action.

  1984cited by this paper

• A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

  2021cites this paper
• Cancer Therapy: Absorbable Delivery Systems

  2015cites this paper
• Taxanes: impact on breast cancer therapy

  2014cites this paper
• Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.

  2014cites this paper
• Phase II trial on neoadjuvant intravenous and trans-uterine arterial chemotherapy for locally advanced bulky cervical adenocarcinoma.

  2013cites this paper
• Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.

  2013cites this paper
• Weekly paclitaxel in heavily pretreated ovarian cancer patients: does this treatment still provide further advantages?

  2012cites this paper
• Phase II Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel as First-Line Therapy for Advanced Gastric Cancer

  2011cites this paper
• 病理病期IB～IIIB期非小細胞肺癌に対するcarboplatin+weekly paclitaxel併用術後化学療法の安全性に関する検討

  2011cites this paper
• Weekly paclitaxel in the treatment of recurrent ovarian cancer

  2010cites this paper
• A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.

  2008cites this paper
• A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer

  2008cites this paper
• Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan

  2007cites this paper
• Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer

  2007cites this paper
• Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.

  2006cites this paper
• Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors

  2006cites this paper
• Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

  2006cites this paper
• Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

  2006cites this paper
• Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study

  2006cites this paper
• Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.

  2005cites this paper
• Treatment options in the management of ovarian cancer

  2005cites this paper
• Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer.

  2005cites this paper
• Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.

  2005cites this paper
• Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up.

  2005cites this paper
• 進行非小細胞肺癌に対するCarboplatin+weekly Paditaxel併用化学療法の第I/II相試験

  2004cites this paper
• A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.

  2004cites this paper
• Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer

  2004cites this paper
• Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.

  2004cites this paper
• Phase II Study of Weekly Paclitaxel for Docetaxel‐Resistant Metastatic Breast Cancer in Japan

  2004cites this paper
• Long-Term, weekly One-Hour Infusion of Paclitaxel in Patients with Metastatic Breast Cancer: A Phase II Monoinstitutional Study

  2004cites this paper
• The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.

  2004cites this paper
• Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study

  2004influential citation
• Cancer Chemotherapy: Past, Present, and Future

  2004cites this paper
• The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.

  2004cites this paper
• Paclitaxel Administered Weekly in Patients with Docetaxel-Resistant Metastatic Breast Cancer: A Single-Center Study

  2004cites this paper
• Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h

  2003cites this paper
• Weekly paclitaxel for advanced non-small cell lung cancer patients not suitable for platinum-based therapy.

  2003cites this paper
• Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study

  2003cites this paper
• Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial

  2003cites this paper
• Consolidation therapies revisited: weekly paclitaxel

  2003cites this paper
• Weekly paclitaxel plus estramustine combination therapy in hormone‐refractory prostate cancer: A pilot study

  2003cites this paper
• A SUCCESSFULLY TREATED CASE OF INFLAMMATORY RECURRENCE AFTER BREAST CONSERVING TREATMENT BY WEEKLY TRASTSUZUMAB-PACLITAXEL THERAPY

  2003cites this paper
• Absorbable Delivery Systems for Cancer Therapy

  2003cites this paper
• Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial

  2003cites this paper
• Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study.

  2002cites this paper
• Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study

  2002cites this paper
• Weekly administration of paclitaxel: theoretical and clinical basis.

  2002cites this paper
• Which dosing scheme is suitable for the taxanes? anin vitro model

  2002cites this paper
• Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

  2002cites this paper
• Role of weekly paclitaxel in the treatment of advanced ovarian cancer.

  2002cites this paper
• Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

  2002cites this paper
• Weekly taxanes in metastatic breast cancer (review).

  2002cites this paper
• Prediction of cell kill kinetics of anticancer agents using the collagen gel droplet embedded-culture drug sensitivity test.

  2002cites this paper
• A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

  2001cites this paper
• Weekly docetaxel in breast cancer: applying clinical data to patient therapy.

  2001cites this paper
• A Dose‐Finding Study of the Weekly Administration of Paclitaxel in Patients With Advanced Solid Tumors

  2001cites this paper
• Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study.

  2001cites this paper
• Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.

  2001cites this paper
• A Phase II Study of Weekly Paclitaxel in Elderly Patients with Advanced Non-Small Cell Lung Cancer 1

  2001cites this paper
• Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

  2001cites this paper
• Docetaxel administered on a weekly basis for metastatic breast cancer.

  2000cites this paper
• Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations.

  2000cites this paper
• UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.

  2000cites this paper
• A phase I study. UFT/leucovorin combined with paclitaxel for anthracycline-pretreated advanced breast cancer.

  2000cites this paper
• Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer

  2000cites this paper
• Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer

  2000influential citation
• UFT/calcium folinate plus weekly paclitaxel for solid tumors.

  1999cites this paper
• A phase II study of biweekly administration of paclitaxel in patients with recurrent epithelial ovarian cancer.

  1999cites this paper
• One-hour paclitaxel infusions: review of safety and efficacy.

  1999cites this paper
• Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.

  1999cites this paper
• UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.

  1999cites this paper
• Cytostatic therapy for metastasized mammary carcinoma – New substances and innovative combinations

  1999cites this paper
• Single-agent paclitaxel in patients with metastatic breast cancer receiving high-dose chemotherapy with peripheral blood stem cell support.

  1999cites this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cites this paper
• Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma.

  1998cites this paper
• Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer.

  1998cites this paper
• Chemotherapeutic Effects on Hematopoiesis: A Mathematical Model

  1998cites this paper
• Paclitaxelof its Use in the Treatment of Metastatic Breast Cancer and Ovarian and Other Gynaecological Cancers

  1998cites this paper
• [Taxanes in the treatment of breast and ovarian cancers: current indications and results].

  1998cites this paper
• Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers.

  1998cites this paper
• Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.

  1998cites this paper
• Taxanes in ovarian cancer treatment.

  1997cites this paper
• Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

  1997cites this paper
• Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.

  1997cites this paper
• Clinical Overview of the Taxanes

  1997cites this paper
• A mathematical model of breast and ovarian cancer treated with paclitaxel.

  1997cites this paper